Trevi Therapeutics (TRVI) Cash from Financing Activities (2018 - 2026)

Trevi Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $222000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 97.45% year-over-year to $222000.0; the TTM figure through Mar 2026 stood at $112.5 million (up 60.26% YoY), while the FY2025 annual figure was $121.0 million, up 96.82% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $222000.0, down from $284000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $110.4 million in Q2 2025, with the low at -$7.7 million in Q2 2023.
• The 5-year median for Cash from Financing Activities is $1.5 million (2023), against an average of $16.8 million.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities slumped 172.48% in 2023, then jumped 95409.26% in 2024.
• Trevi Therapeutics' Cash from Financing Activities stood at $652000.0 in 2022, then plunged by 108.28% to -$54000.0 in 2023, then surged by 95409.26% to $51.5 million in 2024, then sank by 99.45% to $284000.0 in 2025, then retreated by 21.83% to $222000.0 in 2026.
• Business Quant data shows TRVI's Cash from Financing Activities at $222000.0 in Q1 2026, $284000.0 in Q4 2025, and $1.6 million in Q3 2025.